- Home
- ADIL vs CYCC Comparison
ADIL vs CYCC Comparison
Compare ADIL & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- CYCC
- Stock Information
- Founded
- ADIL 2010
- CYCC 1992
- Country
- ADIL United States
- CYCC United States
- Employees
- ADIL N/A
- CYCC N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- CYCC Health Care
- Exchange
- ADIL Nasdaq
- CYCC Nasdaq
- Market Cap
- ADIL 4.3M
- CYCC 3.6M
- IPO Year
- ADIL 2018
- CYCC N/A
- Fundamental
- Price
- ADIL $0.60
- CYCC $0.21
- Analyst Decision
- ADIL Strong Buy
- CYCC Strong Buy
- Analyst Count
- ADIL 1
- CYCC 1
- Target Price
- ADIL $8.00
- CYCC $11.00
- AVG Volume (30 Days)
- ADIL 72.0K
- CYCC 169.8K
- Earning Date
- ADIL 05-13-2025
- CYCC 05-13-2025
- Dividend Yield
- ADIL N/A
- CYCC N/A
- EPS Growth
- ADIL N/A
- CYCC N/A
- EPS
- ADIL N/A
- CYCC N/A
- Revenue
- ADIL N/A
- CYCC $43,000.00
- Revenue This Year
- ADIL N/A
- CYCC N/A
- Revenue Next Year
- ADIL N/A
- CYCC $88.68
- P/E Ratio
- ADIL N/A
- CYCC N/A
- Revenue Growth
- ADIL N/A
- CYCC N/A
- 52 Week Low
- ADIL $0.61
- CYCC $0.20
- 52 Week High
- ADIL $3.10
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- ADIL 36.45
- CYCC 23.01
- Support Level
- ADIL $0.67
- CYCC $0.20
- Resistance Level
- ADIL $0.72
- CYCC $0.32
- Average True Range (ATR)
- ADIL 0.05
- CYCC 0.02
- MACD
- ADIL -0.00
- CYCC -0.01
- Stochastic Oscillator
- ADIL 0.00
- CYCC 5.38
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.